These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date, and reported results 2006-002324-41 A Cancer Research UK Randomised Multicentre Phase II Trial of the DNA-hypomethylating Agent, 5-Aza-2'-deoxycytidine(Decitabine) given intravenously in Combination with Carboplatin, versus Carboplatin ... bad-data
Reported results 2006-002348-27 A Cancer Research UK Phase II Proof of Principle Trial of the activity of the PARP-1 inhibitor, AG-014699, in known carriers of a BRCA 1 or BRCA 2 mutation with locally advanced or metastatic breast o... 2015-01-22 due-trials
Reported results 2006-004149-40 A Cancer Research UK randomised phase II trial of ATN-224 (copper binding agent) in combination with letrozole versus letrozole alone in post-menopausal women with recurrent, oestrogen and/or progeste... 2007-10-04 due-trials
Ongoing, reported early 2007-003240-30 A Cancer Research UK Phase I/II Open Label Study to Evaluate the Safety, Endocrine Effects, and Anti-tumour Activity of Abiraterone Acetate (CB7630) in Patients with Oestrogen (ER) or Androgen Recepto... not-yet-due
Ongoing, reported early 2007-005752-16 A Cancer Research UK randomised phase II trial of ATN-224 (copper binding agent) in combination with exemestane versus exemestane alone in post-menopausal women with recurrent or advanced, oestrogen a... not-yet-due
Reported results 2008-004828-23 A Cancer Research UK Phase II Trial to compare [11C]choline and [18F]choline each given as a single administration via intravenous injection for imaging patients with metastatic prostate cancer 2011-06-06 due-trials
Ongoing, reported early 2008-004829-42 A Cancer Research UK Phase I/IIa Trial of an Oral Notch Inhibitor (MK-0752) in Combination with Gemcitabine in Patients with Stage IV Pancreatic Cancer not-yet-due
Ongoing, reported early 2008-005542-23 A CCLG/Cancer Research UK Phase I Trial of AT9283 (a selective inhibitor of Aurora kinases) given for 72 hours every 21 days via intravenous infusion in children and adolescents with relapsed and refr... not-yet-due
Ongoing, reported early 2009-016952-36 A Cancer Research UK Phase I trial of AT9283 (a selective inhibitor of aurora kinases) given over 72 hrs every 21 days via intravenous infusion in children and adolescents aged 6 months to 18 years wi... not-yet-due
Ongoing 2012-002029-31 A Cancer Research UK Phase I/II study to compare [124I]mIBG PET/CT to [123I]mIBG imaging in patients with metastatic neuroblastoma not-yet-due
Ongoing 2014-000070-19 A Cancer Research UK Phase I Study of MOv18 IgE, a first in class chimeric IgE antibody against folate receptor-α, in patients with advanced solid tumours not-yet-due
Ongoing 2014-004388-20 A Cancer Research UK randomised, double-blind, placebo-controlled Phase IIa trial of AMG 319 given orally as a neoadjuvant therapy in patients with human papillomavirus (HPV) positive and negative hea... not-yet-due